Thromb Haemost 1990; 63(03): 435-438
DOI: 10.1055/s-0038-1645061
Original Articles
Schattauer GmbH Stuttgart

The Use of a Commercial ELISA for Assay of Thrombin-Antithrombin Complexes in Purified Systems

G Elgue
The Department of Clinical Chemistry and Blood Coagulation, Karolinska Institute, Stockholm, Sweden
,
B Pasche
*   The Department of Experimental Surgery, Karolinska Institute, Stockholm, Sweden
,
M Blombäck
The Department of Clinical Chemistry and Blood Coagulation, Karolinska Institute, Stockholm, Sweden
,
p Olsson
*   The Department of Experimental Surgery, Karolinska Institute, Stockholm, Sweden
› Author Affiliations
Further Information

Publication History

Received 20 July 1989

Accepted after revision 19 February 1990

Publication Date:
24 July 2018 (online)

Summary

Inhibition of thrombin by antithrombin III (AT) results in the formation of stable thrombin-AT complexes (TAT). An enzyme-linked immunosorbent assay (ELISA) following the sandwich principle is available for the determination of TAT complexes in human plasma, however, this ELISA method could not be used in purified systems containing thrombin and AT. It has therefore been modified for use in purified systems and an excellent correlation was found between the disappearance of thrombin and AT and the recovery of TAT complexes. Addition of thrombin inhibitor hirudin and heparin inhibitor polybrene into the reacting thrombin-AT mixture did not interfere with the assay of TAT. It was found that the use of siliconised tubes was necessary for the conservation of the TAT complexes.

 
  • References

  • 1 Collen D, DeCock F. Emergence in plasma during activation of the coagulation fibrinolytic systems of neoantigens, associated with the complexes of thrombin or plasmin with their inhibitors. Thromb Res 1974; 5: 777-9
  • 2 Collen D, DeCock F, Verstraete M. Quantitation of thrombin-antithrombin III complexes in human blood. Eur J Clin Invest 1977; 7: 407-11
  • 3 Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/ F1+2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-97
  • 4 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostas 1988; 59: 101-6
  • 5 Fenton JW, Landis BH, Walz DA, Finlayson JS. In: Chemistry and Biology of Thrombin Lundblad RL, Fenton JW, Mann KG. (eds) Ann Arbor Science; 1977. p 52
  • 6 Miller-Andersson M, Borg H, Andersson LO. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 5: 439-52
  • 7 Björk I, Fish WW. Production in vitro and properties of a modified form of bovine antithrombin, cleaved at the active site by thrombin. J Biol Chem 1981; 257: 9487-93
  • 8 Blornbäck M, Blumbäck B, Olsson P, Svendsen L. The assay of antithrombin using a synthetic chromogenic substrate for thrombin. Thromb Res 1974; 5: 621-32
  • 9 Gaffney PJ, Lord K, Brasher M, Kirkwood TB L. Problems in the assay of thrombin using synthetic peptides as substrates. Thromb Res 1977; 10: 549-56